September 15, 2017
News & Publications
Press Releases
September 5, 2017
H3 Biomedicine Announces First Patient Dosed with H3B-6545 in Phase 1 Study in Breast Cancer
Read More »
August 14, 2017
H3 Biomedicine Granted Orphan Drug Designation of H3B-8800 for Treatment of Acute Myelogenous Leukemia and Chronic Myelomonocytic Leukemia
Read More »
July 24, 2017
H3 Biomedicine and University of British Columbia Scientists Report Preclinical Data Describing Immune Evasion Mechanism in Muscle-Invasive Bladder Cancer
Article published in current issue of Nature Communications details that the PPARγ/RXRα pathway constitutes a tumor-intrinsic mechanism underlying immune evasion… Read More »
June 1, 2017
H3 Biomedicine’s Preclinical Data Highlighting Novel Discovery Research around Splicing Modulators Published in Current Issue of Nature Communications
Read More »
May 1, 2017
H3 Biomedicine Appoints Lihua Yu, Ph.D., to Chief Data Sciences Officer
Read More »In the Media
Boston Business Journal
H3 Biomedicine to Begin Trials of First-Ever Gene-Splicing Cancer Drug
Kendall Square-based cancer biotech H3 Biomedicine, created five years ago by Japanese drug firm Eisai, will bring its first drug… Read More »
PharmaVOICE
H3 Biomedicine’s Dr. Lihua Yu Honored in PharmaVOICE 100
In her position as VP, data science and information technology, at H3 Biomedicine, Lihua Yu, Ph.D., is driving the expanded… Read More »
Boston Business Journal
Foundation Medicine, H3 Biomedicine Partner to Develop Cancer Drugs
A partnership announced today between two Cambridge companies, Foundation Medicine (Nasdaq: FMI) and H3 Biomedicine, is further evidence of the… Read More »
FasterCures
Fixes in Financing
High-risk, long-term investments are needed to turn medical innovations into lifesaving therapies. At FasterCures, we examine and highlight innovative funding mechanisms… Read More »Scientific Publications
H3 Biomedicine
Cancer-Associated Mutations in SF3B1 Exhibit Neomorphic Splicing Activity and Block Erythroid Differentiation
Poster Presentation at the 2014 Meeting of the American Society of Hematology on Monday, December 8, 2014. Read More »
ASC Publications
Total Synthesis of 6-Deoxypladienolide D and Assessment of Splicing Inhibitory Activity in a Mutant SF3B1 Cancer Cell Line
A total synthesis of the natural product 6-deoxypladienolide D (1) has been achieved. Two noteworthy attributes of the synthesis are… Read More »
ACS Publications
NAMPT Is the Cellular Target of STF-31-Like Small-Molecule Probes
The small-molecule probes STF-31 and its analogue compound 146 were discovered while searching for compounds that kill VHL-deficient renal cell… Read More »
Nature Chemical Biology
Translational Synthetic Chemistry
Providing chemical matter to modulate newly identified biological targets—as well as pre-existing but chemically intractable ones—remains a challenge in the… Read More »Media Inquiries
For all media interested in speaking to members of H3 Biomedicine’s executive/scientific team, or receiving further information about the company or pipeline, please forward your request to Paul Kidwell.
